TMC1 gene editing therapy for dominant progressive hearing loss

DISEASE CATEGORY: Otologic

INDICATION: Hearing loss

A CRISPR-Cas9-based gene editing therapy targeting TMC1 could prevent DFNA36, a

Read the full 151 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE